Clinical Trial Update: Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809 [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of repeat doses of GSK598809 for substance dependence. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Substance Dependence

Drugs mentioned

• GSK598809 (GSK598809)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Substance Dependence | Phase 1 | Status: COMPLETED